Most Read Articles
Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

Jackey Suen, 2 days ago

Prognostic nutrition index (PNI) strongly predicts clinical outcomes in patients with locally advanced non-small-cell lung cancer (NSCLC), according to two studies presented at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer (WCLC 2018).

Jackey Suen, 09 Oct 2018

LCL161, an experimental inhibitor of apoptosis (IAP) protein antagonist, is shown to improve pathologic complete response (pCR) when added to paclitaxel in selected patients with localized triple-negative breast cancer (TNBC) in neoadjuvant settings.

Biopsy Gleason pattern 5 tied to recurrence, metastasis, mortality in high-risk prostate cancer

29 Nov 2017

Preoperative biopsy Gleason grade (4 + 4 vs any Gleason pattern 5) subclassification of high-risk prostate cancer identifies men at highest risk for progression, according to a study. Furthermore, any Gleason 5 on biopsy correlates with a higher risk of metastasis, as well as prostate cancer-specific and overall mortality.

The authors assessed men with biopsy Gleason sum 8-10 prostate cancer treated with radical prostatectomy. The patients were divided into those with Gleason 4 + 4 vs those with any pattern 5 (ie, Gleason 3 + 5, 5 + 3, 4 + 5, 5 + 4 or 5 + 5).

Kaplan-Meier, log rank test and Cox proportional hazards models were used to analyse the predictors of biochemical recurrence, metastases, and prostate cancer-specific and overall survival.

A total of 634 men at high risk were identified. Of these, 394 (62 percent) had Gleason 4 + 4 and 240 (38 percent) had Gleason pattern 5 on biopsy. There was no significant difference in baseline characteristics between the groups.

Multivariable analysis revealed that men at high risk with Gleason pattern 5 vs Gleason 4 + 4 had no difference in the risk of biochemical recurrence (hazard ratio [HR], 1.26; 95 percent CI, 0.99 to 1.61; p=0.065). However, patients with any Gleason 5 on biopsy had significantly higher risk for metastasis (HR, 2.55; 1.50 to 4.35; p=0.001), prostate cancer-specific mortality (HR, 2.67; 1.26 to 5.66; p=0.010) and overall mortality (HR, 1.60; 1.09 to 2.34; p=0.016).

“Grouping all Gleason 8-10 tumours together as high-risk lesions may fail to fully stratify men at highest risk for poor outcomes,” according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

Jackey Suen, 2 days ago

Prognostic nutrition index (PNI) strongly predicts clinical outcomes in patients with locally advanced non-small-cell lung cancer (NSCLC), according to two studies presented at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer (WCLC 2018).

Jackey Suen, 09 Oct 2018

LCL161, an experimental inhibitor of apoptosis (IAP) protein antagonist, is shown to improve pathologic complete response (pCR) when added to paclitaxel in selected patients with localized triple-negative breast cancer (TNBC) in neoadjuvant settings.